Difference between revisions of "Crizotinib (Xalkori)"
Jump to navigation
Jump to search
m (Text replacement - "[[File:" to "[[:File:") |
m |
||
| Line 25: | Line 25: | ||
*11/20/2013: [http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm376058.htm Approved] for the treatment of patients with metastatic [[Non-small_cell_lung_cancer | non-small cell lung cancer (NSCLC)]] whose tumors are [[Biomarkers#ALK|anaplastic lymphoma kinase (ALK)]]-[[Biomarkers#Rearrangement|positive]]. ''(Indication removed from locally advanced setting; based on PROFILE 1007 and PROFILE 1014)'' | *11/20/2013: [http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm376058.htm Approved] for the treatment of patients with metastatic [[Non-small_cell_lung_cancer | non-small cell lung cancer (NSCLC)]] whose tumors are [[Biomarkers#ALK|anaplastic lymphoma kinase (ALK)]]-[[Biomarkers#Rearrangement|positive]]. ''(Indication removed from locally advanced setting; based on PROFILE 1007 and PROFILE 1014)'' | ||
*3/11/2016: [http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm490391.htm Approved] for the treatment of patients with metastatic [[Non-small_cell_lung_cancer|non-small cell lung cancer (NSCLC)]] whose tumors are [[Biomarkers#ROS1|ROS1]]-[[Biomarkers#Rearrangement|positive]]. ''(New mutation-specific indication; based on PROFILE 1001)'' | *3/11/2016: [http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm490391.htm Approved] for the treatment of patients with metastatic [[Non-small_cell_lung_cancer|non-small cell lung cancer (NSCLC)]] whose tumors are [[Biomarkers#ROS1|ROS1]]-[[Biomarkers#Rearrangement|positive]]. ''(New mutation-specific indication; based on PROFILE 1001)'' | ||
| + | |||
| + | ==History of changes in EMA indication== | ||
| + | *10/23/2012: Initial marketing authorization as Xalkori. | ||
==Also known as== | ==Also known as== | ||
*'''Code names:''' PF02341066, PF-02341066 | *'''Code names:''' PF02341066, PF-02341066 | ||
| − | *'''Brand name:''' Xalkori | + | *'''Brand name:''' Crizalk, Crizocap, Crizonix, Xalkori |
==References== | ==References== | ||
| Line 36: | Line 39: | ||
[[Category:Oral medications]] | [[Category:Oral medications]] | ||
[[Category:Mutation-specific medications]] | [[Category:Mutation-specific medications]] | ||
| − | |||
[[Category:ALK inhibitors]] | [[Category:ALK inhibitors]] | ||
| Line 45: | Line 47: | ||
[[Category:Non-small cell lung cancer medications]] | [[Category:Non-small cell lung cancer medications]] | ||
| + | [[Category:EMA approved in 2012]] | ||
[[Category:FDA approved in 2011]] | [[Category:FDA approved in 2011]] | ||
Revision as of 01:42, 5 December 2021
General information
Class/mechanism: Tyrosine kinase inhibitor; inhibits anaplastic lymphoma kinase (ALK), c-MET and subsequent expression of Hepatocyte Growth Factor Receptor (HGFR), and Recepteur d’Origine Nantais (RON). Inhibits activity of fusion proteins involving ALK, such as EML4-ALK and NPM-ALK.[1][2]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Crizotinib (Xalkori) package insert pages 15-18[1]
- Crizotinib (Xalkori) patient drug information (Chemocare)[3]
- Crizotinib (Xalkori) patient drug information (UpToDate)[4]
History of changes in FDA indication
Anaplastic large cell lymphoma
- 1/14/2021: Approved for pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. (New disease entity; based on ADVL0912)
Non-small cell lung cancer
- 8/26/2011: Initial accelerated approval for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK)-positive. (Based on PROFILE 1001)
- 11/20/2013: Approved for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive. (Indication removed from locally advanced setting; based on PROFILE 1007 and PROFILE 1014)
- 3/11/2016: Approved for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive. (New mutation-specific indication; based on PROFILE 1001)
History of changes in EMA indication
- 10/23/2012: Initial marketing authorization as Xalkori.
Also known as
- Code names: PF02341066, PF-02341066
- Brand name: Crizalk, Crizocap, Crizonix, Xalkori